The healthcare industry in 2026 has transitioned from a period of experimental artificial intelligence fervour to a phase of rigorous industrialisation, where the value of technology is measured by its ability to stabilise margins and secure sensitive data rather than its capacity for high-profile public spectacle. International Business Machines (IBM), having navigated a decade of volatility in its Watson Health division, has executed a profound strategic re-entry into the s